Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: The Belgian FExT study

Tony Mets, Maurits Vandewoude, Jean Jacquy, Anne Deblander, Karen MacDonald, Anne Sloesen, Ivo Abraham

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Objective: Despite response variability, Cholinesterase inhibitors are recommended in mild to moderate Alzheimer's disease. Dose titration is common; however randomized controlled trials (RCTs) have mainly investigated fixed-dose regimens. We examined practice patterns and outcomes of 6 ± 1.5-month rivastigmine therapy. Methods: Prospective, pharmacoepidemiologic, naturalistic study of 175 evaluable patients with mild to moderate Alzheimer's disease (+ 151 caregivers) from 52 centers in Belgium on 6 ± 1.5 month (titrated) rivastigmine treatment. Main outcome measures: Measured at baseline (enrollment) and follow-up (6 ± 1.5 months). For patients: Mini-Mental State Exam (MMSE), Activities of Daily Living (ADL), Neuropsychiatric Inventory (NPI), Global Deterioration Scale (GDS) scores; treatment response (improvement, maintenance, or decline less than normative slope). For caregivers: hours/week spent caring; Zarit Caregiver Burden Scale (ZCBS), 12-item version of General Health Questionnaire (GHQ-12), Instrumental Activities of Daily Living (IADL) scores.

Original languageEnglish (US)
Pages (from-to)2485-2501
Number of pages17
JournalCurrent Medical Research and Opinion
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2007

Keywords

  • Alzheimer's disease
  • Evidence-based medicine
  • Outcomes research
  • Pharmacoepidemiology
  • Rivastigmine
  • Treatment effectiveness

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: The Belgian FExT study'. Together they form a unique fingerprint.

  • Cite this